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Dear Editor,
This paper introduces MTs as metalloproteins and their
role in various inﬂammatory diseases. In the conclusion
section, the authors state that MT-induction/enhancement
and/or zinc supplementation to induce/enhance MT might
be possible therapeutic options for inﬂammatory diseases
[1].
To be an appropriate therapy on the level of genetics or
molecule, the option should be well meditated because the
targeting network for a cellular process is so complicated.
First do no harm, which is the foremost principle for a
therapy [2]. However, there is scarce any medical good
without its concomitant harm. For example, it is reported
that antibiotic treatment of bacterial infection, even if being
successful, hinders development of acquired immunity so
that the immune responses of the host confer no protection
to secondary infection [3]. Anyway, the proposal for a
therapeutic option needs discretion.
Unfortunately, inﬂammation events and evidence pro-
vided in this paper are not suﬃcient enough to support
MT as an anti-inﬂammatory mediator. Traumatic injury is
not the mainstay of inﬂammatory diseases, and restrained
inﬂammation is regarded as beneﬁcial for host wound
healing and defense toward infection [4]. Acute liver injury
has quite diﬀerent pathophysiology compared to viral hep-
atitis, liver cirrhosis, and liver cancer, which are chronic.
Mechanism of anti-inﬂammatory mediation needs clearer
presentation.
Both MT and zinc are tightly regulated in the body.
Zinc is crucial for the activation and binding of certain
transcription factors through the participation in the zinc
ﬁnger region of MT. Thus, MT regulates the level of zinc by
binding and releasing this essential trace element. Too much
zinc is also harmful to the body with resultant intoxication
[5]. Surplus zinc is captured by MT the same as it detoxiﬁes
other heavy metals by forming inclusions and crystals
[6, 7].
Simply inducing or enhancing MT is harmful because
both increased and decreased expression of MT lead to
malignant transformation of cells and ultimately cancer [8].
The former is found in several cancers including that of the
breast, colon, and prostate, while the latter is detected in liver
cancer [9]. In addition, higher levels of MT expression have
proved to result in chemoresistance to drugs [10].
I would suggest ﬁne tuning rather than sole induction or
enhancement of MT, discussing one particular inﬂammatory
disease instead of generalized ones, and investigating the
eﬀects of both increased and decreased MT expression with
emphasis on the homeostasis of this mediator. In addition,
zinc supplementation is indicated to zinc deﬁciency not to
inﬂammation.
Yong-Song Guan
References
[1] K. Inoue, H. Takano, A. Shimada, and M. Satoh, “Metal-
lothionein as an anti-inﬂammatory mediator,” Mediators of
Inﬂammation, vol. 2009, Article ID 101659, 7 pages, 2009.
[2] X. Zhang, “Ethical reﬂection on human gene therapy in the
Chinesecontext,”InternationalJournalofBioethics,vol.19,no.
4, pp. 95–104, 163, 2008.
[3] A. Griﬃn, D. Baraho-Hassan, and S. J. McSorley, “Successful
treatment of bacterial infection hinders development of
acquired immunity,” The Journal of Immunology. In press.
[4] T. Glaros, M. Larsen, and L. Li, “Macrophages and ﬁbroblasts
during inﬂammation, tissue damage and organ injury,” Fron-
tiers in Bioscience, vol. 14, pp. 3988–3993, 2009.2 Mediators of Inﬂammation
[5] S. Pawa, A. J. Khalifa, M. N. Ehrinpreis, C. A. Schiﬀer, and
F. A. Siddiqui, “Zinc toxicity from massive and prolonged
coin ingestion in an adult,” American Journal of the Medical
Sciences, vol. 336, no. 5, pp. 430–433, 2008.
[ 6 ]G .P .B o r r e l l y ,M .D .H a r r i s o n ,A .K .R o b i n s o n ,S .G .C o x ,N .
J. Robinson, and S. K. Whitehall, “Surplus zinc is handled by
Zym1 metallothionein and Zhf endoplasmic reticulum trans-
porter in Schizosaccharomyces pombe,” Journal of Biological
Chemistry, vol. 277, no. 33, pp. 30394–30400, 2002.
[ 7 ]H .C .C h i a n g ,J .C .L o ,a n dK .C .Y e h ,“ G e n e sa s s o c i a t e d
with heavy metal tolerance and accumulation in Zn/Cd
hyperaccumulator Arabidopsis halleri: a genomic survey with
cDNAmicroarray,”EnvironmentalScienceandTechnology,vol.
40, no. 21, pp. 6792–6798, 2006.
[8] S. Krizkova, I. Fabrik, V. Adam, J. Hrabeta, T. Eckschlager,
and R. Kizek, “Metallothionein—a promising tool for cancer
diagnostics,” Bratisl Lek Listy, vol. 110, no. 2, pp. 93–97, 2009.
[9] J. Datta, S. Majumder, H. Kutay, et al., “Metallothionein
expression is suppressed in primary human hepatocellu-
lar carcinomas and is mediated through inactivation of
CCAAT/enhancer binding protein α by phosphatidylinositol
3-kinase signaling cascade,” Cancer Research, vol. 67, no. 6, pp.
2736–2746, 2007.
[10] X. Yap, H. Y. Tan, J. Huang, et al., “Over-expression of
metallothionein predicts chemoresistance in breast cancer,”
Journal of Pathology, vol. 217, no. 4, pp. 563–570, 2009.